New York City-based AI and advanced data analytics company, AiCure, has recently achieved significant milestones, securing a $12M loan refinancing and an additional $4M+ from existing investors. This funding infusion positions AiCure to further its mission of revolutionizing clinical trials through innovative AI solutions.

With a focus on research and development, the company plans to enhance its products and services, expand operations, and solidify its presence in the life sciences industry. AiCure’s unique software and technology aim to improve patient engagement and sponsor insights in clinical trials, contributing to advancements in drug development and patient care.

In 2023, AiCure obtained seven new US patents, bringing its total patent count to 86 worldwide. These patents reinforce the company’s digital biomarker solutions and support its core business areas, emphasizing AiCure’s commitment to technological leadership.

Adding to its accomplishments, AiCure welcomed two seasoned professionals to its Senior Leadership Team. Sondra Pepe, with nearly two decades of experience in eClinical SaaS technology, joins as the Senior Vice President of Product Management. Josh Wilson, a veteran with almost 20 years in data management and technology implementation, assumes the role of Senior Vice President of Operations.

The company’s dedication to diversity and inclusivity is evident, with 42% of its workforce represented by women, led by Vice President of People Operations, Earnest Offley. AiCure’s responsible AI practices, including self-checks to mitigate racial pigmentation bias, showcase its commitment to fostering an inclusive workplace and equitable customer studies.

AiCure’s unique approach to medication adherence tracking sets it apart. Utilizing a visual recognition system, the company’s software confirms patient medication ingestion without recording video or taking photos. This scalable and flexible solution addresses the complexities of medication adherence, contributing to improved outcomes in clinical trials and population health applications.

The recent funding round of $16M, coupled with AiCure’s expanding patent portfolio, growing customer base, and strategic leadership initiatives, positions the company for continued success. As AiCure looks ahead to 2024, its commitment to enhancing drug development and patient care through innovative AI solutions remains unwavering.

For more information about AiCure and its groundbreaking advancements, please visit the AiCure website.